113 related articles for article (PubMed ID: 7988058)
1. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumours.
Zhu GG; Melkko J; Risteli J; Kauppila A; Risteli L
Clin Chim Acta; 1994 Sep; 229(1-2):87-97. PubMed ID: 7988058
[TBL] [Abstract][Full Text] [Related]
2. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.
Zhu GG; Risteli J; Puistola U; Kauppila A; Risteli L
Cancer Res; 1993 Oct; 53(20):5028-32. PubMed ID: 8402695
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.
Santala M; Risteli J; Risteli L; Puistola U; Kacinski BM; Stanley ER; Kauppila A
Br J Cancer; 1998 Jun; 77(11):1825-31. PubMed ID: 9667653
[TBL] [Abstract][Full Text] [Related]
4. Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.
Punnonen J; Heinonen PK; Kuoppala T; Jansen CT; Punnonen R
J Cancer Res Clin Oncol; 1991; 117(6):587-92. PubMed ID: 1744165
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells.
Sowter HM; Corps AN; Smith SK
Int J Cancer; 1999 Nov; 83(4):476-80. PubMed ID: 10508482
[TBL] [Abstract][Full Text] [Related]
6. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas.
Kauppila S; Saarela J; Stenbäck F; Risteli J; Kauppila A; Risteli L
Am J Pathol; 1996 Feb; 148(2):539-48. PubMed ID: 8579116
[TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of the N-terminal propeptide of human type III procollagen.
Niemelä O; Risteli L; Parkkinen J; Risteli J
Biochem J; 1985 Nov; 232(1):145-50. PubMed ID: 4084223
[TBL] [Abstract][Full Text] [Related]
8. Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival.
Cracchiolo BM; Hanauske-Abel HM; Schwartz PE; Chambers JT; Holland B; Chambers SK
Gynecol Oncol; 2002 Oct; 87(1):24-33. PubMed ID: 12468338
[TBL] [Abstract][Full Text] [Related]
9. Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo.
Kauppila S; Bode MK; Stenbäck F; Risteli L; Risteli J
Br J Cancer; 1999 Oct; 81(4):654-61. PubMed ID: 10574251
[TBL] [Abstract][Full Text] [Related]
10. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
Sundfeldt K; Ivarsson K; Rask K; Haeger M; Hedin L; Brännström M
Anticancer Res; 2001; 21(1A):65-70. PubMed ID: 11299791
[TBL] [Abstract][Full Text] [Related]
11. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Wahlberg K; Høyer-Hansen G; Casslén B
Cancer Res; 1998 Aug; 58(15):3294-8. PubMed ID: 9699658
[TBL] [Abstract][Full Text] [Related]
12. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
14. Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum.
Puistola U; Risteli L; Risteli J; Kauppila A
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1276-81. PubMed ID: 2220941
[TBL] [Abstract][Full Text] [Related]
15. Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours.
Haeger M; Swahn M; Hahlin M; Horvath G; Bengtsson A
Anticancer Res; 1996; 16(5B):3189-92. PubMed ID: 8967734
[TBL] [Abstract][Full Text] [Related]
16. Measurement of glycodelin A in fluids of benign ovarian cysts, borderline tumours and malignant ovarian cancer.
Bischof A; Briese V; Richter DU; Bergemann C; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1639-44. PubMed ID: 16033074
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma.
Halperin R; Pansky M; Vaknin Z; Zehavi S; Bukovsky I; Schneider D;
Eur J Obstet Gynecol Reprod Biol; 2003 Oct; 110(2):207-10. PubMed ID: 12969585
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.
Wilson AP; Fox H; Scott IV; Lee H; Dent M; Golding PR
Br J Cancer; 1991 Jan; 63(1):102-8. PubMed ID: 1989647
[TBL] [Abstract][Full Text] [Related]
19. Aminoterminal propeptide of type III procollagen in healing wound in humans.
Haukipuro K; Risteli L; Kairaluoma MI; Risteli J
Ann Surg; 1987 Dec; 206(6):752-6. PubMed ID: 3689011
[TBL] [Abstract][Full Text] [Related]
20. Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies.
Sipak-Szmigiel O; Włodarski P; Ronin-Walknowska E; Niedzielski A; Karakiewicz B; Słuczanowska-Głąbowska S; Laszczyńska M; Malinowski W
J Ovarian Res; 2017 Apr; 10(1):25. PubMed ID: 28376925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
